Colleen Kusy
Stock Analyst at Baird
(1.66)
# 3,425
Out of 5,154 analysts
52
Total ratings
35.56%
Success rate
-0.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintains: Outperform | $9 → $12 | $7.18 | +67.13% | 2 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $717.79 | +20.79% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $99.41 | +58.94% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $37.08 | -8.31% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $20.07 | +159.09% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $10.27 | +133.69% | 5 | Oct 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $29.44 | +76.63% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $2.96 | +102.70% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $26.96 | +52.08% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.82 | +229.67% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $40.15 | +61.89% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $13.71 | +82.35% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $8.77 | +2,294.53% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $5.13 | +562.77% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.79 | +5,968.60% | 1 | Nov 2, 2021 |
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $7.18
Upside: +67.13%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $717.79
Upside: +20.79%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $99.41
Upside: +58.94%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $37.08
Upside: -8.31%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $20.07
Upside: +159.09%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $10.27
Upside: +133.69%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $29.44
Upside: +76.63%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $2.96
Upside: +102.70%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $26.96
Upside: +52.08%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.82
Upside: +229.67%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $40.15
Upside: +61.89%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $13.71
Upside: +82.35%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $8.77
Upside: +2,294.53%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $5.13
Upside: +562.77%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.79
Upside: +5,968.60%